Home

March Neurogenesis talks explore brain mechanisms in food choice and computational modelling

Published: 1 April 2025

Last week, HBHL hosted the third talk of the 2024-2025 Neurogenesis Speaker Series at the Neuro, featuring Dana Small and Yashar Zeighami....

AI analysis of healthcare records reveals key factors in autism diagnosis

Published: 26 March 2025

Scientists argue the criteria we use for diagnosing autism may need revision...

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Published: 14 March 2025

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation...

6th National Course on Sleep Medicine

Friday, November 28, 2025 09:00toSaturday, November 29, 2025 16:00

This two-day training course is designed to provide and enhance a basic working knowledge of sleep medicine.3801 rue University, Montreal, QC, H3A 2B4, CA/neuroCategory: Medicine Research...

Project to create AI model for ALS receives Génome Québec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

2025 Hughlings Jackson Lecture: The Basal Ganglia and the Motivation to Act

Thursday, November 13, 2025 16:00to17:00

Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honours the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the...

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on Parkinson’s, glioblastoma and dementia  

Latest Alzheimer’s drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...

Pages

Subscribe to External RSS

TWITTER

Back to top